A.L.P.S. Clavicle Plating System PMCF

February 10, 2026 updated by: Zimmer Biomet

A.L.P.S. Clavicle Plating System for Clavicle Fracture Fixation Post-Market Follow-up Study (Implants and Instrumentation)

A commercially available product clinical study which aims to confirm the safety, performance, and clinical benefits to the patient of the ALPS Clavicle Plating system for both the implant itself and the instrumentation used during surgery.

Study Overview

Status

Active, not recruiting

Detailed Description

The objectives of this observational, prospective study with optional retrospective enrollment are to confirm safety, performance and clinical benefits of the A.L.P.S Clavicle Plating System and its instrumentation by analysis of fracture healing, functional outcome and adverse events.

The safety of the system will be assessed by monitoring the frequency and incidence of adverse events including re-operations. Relation of the events to implant, instrumentation and/or procedure should be specified.

The performance will be evaluated by assessment of fracture/osteotomy healing and functional outcome of all enrolled study subjects.

Study Type

Interventional

Enrollment (Actual)

98

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Valladolid, Spain, 47002
        • General Foundation of the University of Valladolid
    • Florida
      • Weston, Florida, United States, 33331
        • Cleveland Clinic Florida
    • Michigan
      • Ann Arbor, Michigan, United States, 48137
        • University of Michigan - Michigan Medicine
    • Oregon
      • Eugene, Oregon, United States, 97401
        • Slocum Research & Education Foundation
    • Texas
      • San Antonio, Texas, United States, 78229
        • University of Texas San Antonio

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Patient must be 18 years of age or older.
  • Patient must have a clavicle fracture requiring surgical intervention and be eligible for fixation by locking plate and screws.
  • Unilateral or Bilateral fractures.
  • Patient must be capable of understanding the doctor's explanation, following doctor's instruction, is able to and willing to complete the protocol required follow-up.
  • Patient must have a signed IRB/EC approved informed consent.

Exclusion Criteria:

  • Active infection.
  • Patients presenting conditions including blood supply limitations, insufficient quantity or quality of bone.
  • Patients with mental or neurologic conditions who are unwilling or incapable of giving proper informed consent, following postoperative care instructions.
  • Foreign body sensitivity where material sensitivity is suspected, testing is to be completed prior to implantation of the device.
  • Patient is a current alcohol or drug abuser
  • Patient is a prisoner
  • Patient known to be pregnant or breast feeding
  • Likely problems with maintaining follow-up program (e.g. patient with no fixed address, long distance, plans to move during course of study)
  • Not expected to survive the duration of the follow-up program

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment Group
The population target is all subjects suffering clavicle fracture suitable for open reduction and internal fixation by the A.L.P.S. Clavicle Plating System in accordance with the IFU.
Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of subjects with fracture healing
Time Frame: 12 months
Number of subjects with fracture healing will be assessed through 12 months follow-up. Radiologic fracture healing is defined as: Bridging callus or no visible fracture lines on AP and 15-45° cephalic oblique radiographs.
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency and Incidence of Adverse Events (Safety)
Time Frame: 12 months
Monitoring the frequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated serious adverse device effects as well as device deficiencies.
12 months
Range of Motion - Total shoulder motion
Time Frame: 12 months
Range of Motion (affected and contralateral), Forward elevation (maximum arm-trunk angle), External rotation (arm comfortably at side), External rotation (arm at 90 degrees of abduction), Internal rotation (thumb to back) spinous process, Cross-body adduction (antecubital fossa to opposite acromion (cm)
12 months
Clinical efficacy of the device is assessed using the American Shoulder and Elbow Surgeons (ASES) Shoulder Score at 12 months follow-up
Time Frame: 12 months
The ASES scale is 0-100. 100 is the highest score and indicates the greatest function while 0 is the lowest score.
12 months
Euroqol Patient Quality of life measured at 12 months follow-up (EQ-5D-5L)
Time Frame: 12 months
The EuroQol five dimensions questionnaire (EQ-5D-5L) is a five dimensional self-assessment that is comprised of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. These five dimensions can be used to index a subject's health utility on a scale of 0 to 1, where 0 is death and 1 is perfect health. The scoring rule for EQ-5D permits scores less than 0, implying that some health states may be worse than death.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Hillary Overholser, Zimmer Biomet

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 13, 2022

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

March 1, 2027

Study Registration Dates

First Submitted

March 10, 2022

First Submitted That Met QC Criteria

April 13, 2022

First Posted (Actual)

April 14, 2022

Study Record Updates

Last Update Posted (Actual)

February 13, 2026

Last Update Submitted That Met QC Criteria

February 10, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Clavicle Fracture

Clinical Trials on Clavicle open reduction and internal fixation

Subscribe